We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Roche Announces Positive Data on Lung Cancer Drug Alecensa
Read MoreHide Full Article
Roche Holdings AG (RHHBY - Free Report) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. The study met its primary endpoint as data from the study demonstrated that Alecensa significantly improved progression-free survival (PFS) in patients.
Those suffering from anaplastic lymphoma kinase (ALK)-positive advanced (metastatic) non-small cell lung cancer (NSCLC) and had progressed following treatment with one prior line of both platinum-based chemotherapy and Pfizer’s (PFE - Free Report) Xalkori, compared with chemotherapy are likely to benefit from the same.
We remind investors that Alecensa received conditional marketing authorisation from the European Commission in patients suffering from ALK-positive NSCLC previously treated with Xalkori in Feb 2017.
The drug is also approved as a monotherapy for patients suffering from ALK-positive NSCLC who have progressed on or are intolerant to Xalkori.
Meanwhile, Alecensa is also being evaluated as a first-line treatment option in phase III study, ALEX, comparing Alecensa to Xalkori in ALK-positive NSCLC. The study is expected to report data in the first half of 2017.
There is a significant need for lung cancer treatments as approximately 75,000 people globally are diagnosed with ALK-positive NSCLC every year.
Roche’s share price shows that the company has outperformed the Zacks classified industry year to date. The stock rallied 12.8% compared to the Large Cap Pharmaceuticals industry’s gain of 6.6%.
We remind investors that Novartis (NVS - Free Report) is also evaluating Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK+positive as detected by an FDA-approved test.
Concurrently, Roche launched CE-IVD launch of the cobas Liat PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect clostridium difficile.
Roche has a strong presence in the oncology market. The company dominates the breast cancer space with strong demand for HER2 franchise drugs like Herceptin, Perjeta and Kadcyla. We are also impressed by the company's efforts to develop its portfolio beyond oncology into immunology. New drug launches, such as Tecentriq, Cotellic and Alecensa boosted sales and are expected to continue to do so in the upcoming quarters as well.
Zacks Rank & Stock to Consider
Roche currently sports a Zacks Rank #1 (Strong Buy).
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018 over the last 30 days. The company posted a positive earnings surprise in all the four trailing quarters with an average beat of 291.54%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
Roche Announces Positive Data on Lung Cancer Drug Alecensa
Roche Holdings AG (RHHBY - Free Report) recently announced encouraging results from the phase III study, ALUR on lung cancer drug Alecensa. The study met its primary endpoint as data from the study demonstrated that Alecensa significantly improved progression-free survival (PFS) in patients.
Those suffering from anaplastic lymphoma kinase (ALK)-positive advanced (metastatic) non-small cell lung cancer (NSCLC) and had progressed following treatment with one prior line of both platinum-based chemotherapy and Pfizer’s (PFE - Free Report) Xalkori, compared with chemotherapy are likely to benefit from the same.
We remind investors that Alecensa received conditional marketing authorisation from the European Commission in patients suffering from ALK-positive NSCLC previously treated with Xalkori in Feb 2017.
The drug is also approved as a monotherapy for patients suffering from ALK-positive NSCLC who have progressed on or are intolerant to Xalkori.
Meanwhile, Alecensa is also being evaluated as a first-line treatment option in phase III study, ALEX, comparing Alecensa to Xalkori in ALK-positive NSCLC. The study is expected to report data in the first half of 2017.
There is a significant need for lung cancer treatments as approximately 75,000 people globally are diagnosed with ALK-positive NSCLC every year.
Roche’s share price shows that the company has outperformed the Zacks classified industry year to date. The stock rallied 12.8% compared to the Large Cap Pharmaceuticals industry’s gain of 6.6%.
We remind investors that Novartis (NVS - Free Report) is also evaluating Zykadia (ceritinib) as a first-line treatment for patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ALK+positive as detected by an FDA-approved test.
Concurrently, Roche launched CE-IVD launch of the cobas Liat PCR System with four assays including first 20 minute real-time PCR nucleic acid test to detect clostridium difficile.
Roche has a strong presence in the oncology market. The company dominates the breast cancer space with strong demand for HER2 franchise drugs like Herceptin, Perjeta and Kadcyla. We are also impressed by the company's efforts to develop its portfolio beyond oncology into immunology. New drug launches, such as Tecentriq, Cotellic and Alecensa boosted sales and are expected to continue to do so in the upcoming quarters as well.
Zacks Rank & Stock to Consider
Roche currently sports a Zacks Rank #1 (Strong Buy).
Another favorably placed stock in the healthcare sector includes Heska Corp. . You can see the complete list of today’s Zacks #1 Rank stocks here.
Heska’s earnings estimates increased from $1.53 to $1.65 for 2017 and from $1.90 to $2.01 for 2018 over the last 30 days. The company posted a positive earnings surprise in all the four trailing quarters with an average beat of 291.54%.
Zacks’ Best Private Investment Ideas
In addition to the recommendations that are available to the public on our website, how would you like to follow all Zacks' private buys and sells in real time?
Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Starting today, for the next month, you can have unrestricted access. Click here for Zacks' private trades >>